1
|
Tu R, Zhong D, Li P, Li Y, Chen Z, Hu F, Yuan G, Chen Z, Yu S, Song J. PTPN13 rs989902 and CHEK2 rs738722 are associated with esophageal cancer. Ann Med 2023; 55:2281659. [PMID: 38039548 PMCID: PMC10836260 DOI: 10.1080/07853890.2023.2281659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Accepted: 11/03/2023] [Indexed: 12/03/2023] Open
Abstract
PURPOSE Individual genetic background can play an essential role in determining the development of esophageal squamous cell carcinoma (ESCC). PTPN13 and CHEK2 play important roles in the pathogenesis of ESCC. This case-control study aimed to analyze the association between gene polymorphisms and ESCC susceptibility. METHODS DNA was extracted from the peripheral blood of patients. The Agena MassARRAY platform was used for the genotyping. Statistical analysis was conducted using the chi-squared test or Fisher's exact test, logistic regression analysis, and stratification analysis. RESULTS The 'G' allele of rs989902 (PTPN13) and the 'T' allele of rs738722 (CHEK2) were both associated with an increased risk of ESCC (rs989902: OR = 1.23, 95% CI = 1.02-1.47, p = 0.028; rs738722: OR = 1.28, 95% CI = 1.06-1.55, p = 0.011). Stratification analysis showed that SNPs (rs989902 and rs738722) were notably correlated with an increased risk of ESCC after stratification for age, sex, smoking, and drinking status. In addition, rs738722 might be associated with lower stage, while rs989902 had a lower risk of metastasis. CONCLUSION Our findings display that PTPN13 rs989902 and CHEK2 rs738722 are associated with an increased risk of ESCC in the Chinese Han population.
Collapse
Affiliation(s)
- Ruisha Tu
- Department of Gastrointestinal Surgery, Hainan Cancer Hospital, Haikou, Hainan, China
| | - Dunjing Zhong
- Department of Gastroenterology, Hainan Cancer Hospital, Haikou, Hainan, China
| | - Ping Li
- Department of Digestive Endoscopy Center, Hainan Cancer Hospital, Haikou, Hainan, China
| | - Yongyu Li
- Department of Gastroenterology, Hainan Cancer Hospital, Haikou, Hainan, China
| | - Zhuang Chen
- Department of Gastroenterology, Hainan Cancer Hospital, Haikou, Hainan, China
| | - Feixiang Hu
- Department of Gastrointestinal Surgery, Hainan Cancer Hospital, Haikou, Hainan, China
| | - Guihong Yuan
- Department of Gastroenterology, Hainan Cancer Hospital, Haikou, Hainan, China
| | - Zhaowei Chen
- Department of Gastroenterology, Hainan Cancer Hospital, Haikou, Hainan, China
| | - Shuyong Yu
- Department of Gastrointestinal Surgery, Hainan Cancer Hospital, Haikou, Hainan, China
| | - Jian Song
- Department of Digestive Endoscopy Center, Hainan Cancer Hospital, Haikou, Hainan, China
- Department of Gastroenterology, Southern University of Science and Technology Hospital, Shenzhen, Guangdong, China
| |
Collapse
|
2
|
Aptecar L, Puech C, Lopez-Crapez E, Peter M, Coopman P, D’Hondt V, Freiss G. PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells. Int J Mol Sci 2023; 24:15413. [PMID: 37895093 PMCID: PMC10607604 DOI: 10.3390/ijms242015413] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 10/19/2023] [Indexed: 10/29/2023] Open
Abstract
Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological cancers in Western countries. High-Grade Serous Ovarian Carcinoma (HGSOC) accounts for 60-70% of EOC and is the most aggressive subtype. Reduced PTPN13 expression levels have been previously correlated with worse prognosis in HGSOC. However, PTPN13's exact role and mechanism of action in these tumors remained to be investigated. To elucidate PTPN13's role in HGSOC aggressiveness, we used isogenic PTPN13-overexpressing clones of the OVCAR-8 cell line, which poorly expresses PTPN13, and also PTPN13 CRISPR/Cas9-mediated knockout/knockdown clones of the KURAMOCHI cell line, which strongly expresses PTPN13. We investigated their migratory and invasive capacity using a wound healing assay, their mesenchymal-epithelial transition (EMT) status using microscopy and RT-qPCR, and their sensitivity to chemotherapeutic drugs used for HGSOC. We found that (i) PTPN13 knockout/knockdown increased migration and invasion in KURAMOCHI cells that also displayed a more mesenchymal phenotype and increased expression of the SLUG, SNAIL, ZEB-1, and ZEB-2 EMT master genes; and (ii) PTPN13 expression increased the platinum sensitivity of HGSOC cells. These results suggest that PTPN13 might be a predictive marker of response to platinum salts in HGSOC.
Collapse
Affiliation(s)
- Leticia Aptecar
- IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France (E.L.-C.)
| | - Carole Puech
- IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France (E.L.-C.)
| | - Evelyne Lopez-Crapez
- IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France (E.L.-C.)
| | - Marion Peter
- IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France (E.L.-C.)
- CNRS—Centre National de la Recherche Scientifique, 1919 Route de Mende, F-34293 Montpellier, France; (M.P.); (P.C.)
| | - Peter Coopman
- IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France (E.L.-C.)
- CNRS—Centre National de la Recherche Scientifique, 1919 Route de Mende, F-34293 Montpellier, France; (M.P.); (P.C.)
| | - Véronique D’Hondt
- IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France (E.L.-C.)
| | - Gilles Freiss
- IRCM (Institut de Recherche en Cancérologie de Montpellier), University of Montpellier, Inserm, ICM (Institut du Cancer de Montpellier), F-34000 Montpellier, France (E.L.-C.)
| |
Collapse
|
3
|
Wang Y, Brazdzionis J, Dong F, Patchana T, Ghanchi H, Podkovik S, Wiginton JG, Marino M, Duong J, Wacker M, Miulli DE, Neeki M, Bi X, Baudry M. P13BP, a Calpain-2-Mediated Breakdown Product of PTPN13, Is a Novel Blood Biomarker for Traumatic Brain Injury. J Neurotrauma 2021; 38:3077-3085. [PMID: 34498916 DOI: 10.1089/neu.2021.0229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
Abstract
Biomarkers play an increasing role in medicinal biology. They are used for diagnosis, management, drug target identification, drug responses, and disease prognosis. We have discovered that calpain-1 and calpain-2 play opposite functions in neurodegeneration, with calpain-1 activation being neuroprotective, while prolonged calpain-2 activation is neurodegenerative. This notion has been validated in several mouse models of acute neuronal injury, in particular in mouse models of traumatic brain injury (TBI) and repeated concussions. We have identified a selective substrate of calpain-2, the tyrosine phosphatase, PTPN13, which is cleaved in brain after TBI. One of the fragments generated by calpain-2, referred to as P13BP, is also found in the blood after TBI both in mice and humans. In humans, P13BP blood levels are significantly correlated with the severity of TBI, as measured by Glasgow Coma Scale scores and loss of consciousness. The results indicate that P13BP represents a novel blood biomarker for TBI.
Collapse
Affiliation(s)
- Yubin Wang
- Western University of Health Sciences, Pomona Valley, California, USA
| | - James Brazdzionis
- Riverside University Health System Medical Center, Moreno Valley, California, USA
| | - Fanglong Dong
- Western University of Health Sciences, Pomona Valley, California, USA
| | - Tye Patchana
- Riverside University Health System Medical Center, Moreno Valley, California, USA
| | - Hammad Ghanchi
- Riverside University Health System Medical Center, Moreno Valley, California, USA
| | - Stacey Podkovik
- Riverside University Health System Medical Center, Moreno Valley, California, USA
| | - James G Wiginton
- Riverside University Health System Medical Center, Moreno Valley, California, USA
| | - Maxwell Marino
- Riverside University Health System Medical Center, Moreno Valley, California, USA
| | - Jason Duong
- Arrowhead Regional Medical Center, Colton, California, USA
| | | | - Dan E Miulli
- Arrowhead Regional Medical Center, Colton, California, USA
| | - Michael Neeki
- Arrowhead Regional Medical Center, Colton, California, USA
| | - Xiaoning Bi
- Western University of Health Sciences, Pomona Valley, California, USA
| | - Michel Baudry
- Western University of Health Sciences, Pomona Valley, California, USA
| |
Collapse
|
4
|
Mcheik S, Aptecar L, Coopman P, D'Hondt V, Freiss G. Dual Role of the PTPN13 Tyrosine Phosphatase in Cancer. Biomolecules 2020; 10:E1659. [PMID: 33322542 DOI: 10.3390/biom10121659] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 12/07/2020] [Accepted: 12/09/2020] [Indexed: 02/08/2023] Open
Abstract
In this review article, we present the current knowledge on PTPN13, a class I non-receptor protein tyrosine phosphatase identified in 1994. We focus particularly on its role in cancer, where PTPN13 acts as an oncogenic protein and also a tumor suppressor. To try to understand these apparent contradictory functions, we discuss PTPN13 implication in the FAS and oncogenic tyrosine kinase signaling pathways and in the associated biological activities, as well as its post-transcriptional and epigenetic regulation. Then, we describe PTPN13 clinical significance as a prognostic marker in different cancer types and its impact on anti-cancer treatment sensitivity. Finally, we present future research axes following recent findings on its role in cell junction regulation that implicate PTPN13 in cell death and cell migration, two major hallmarks of tumor formation and progression.
Collapse
|
5
|
Long Q, Sun J, Lv J, Liang Y, Li H, Li X. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling. Exp Cell Res 2020; 396:112286. [PMID: 32919955 DOI: 10.1016/j.yexcr.2020.112286] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2020] [Revised: 09/04/2020] [Accepted: 09/09/2020] [Indexed: 01/24/2023]
Abstract
Protein tyrosine phosphatase, nonreceptor type 13 (PTPN13), has emerged as a critical cancer-related gene that is implicated in a wide range of cancer types. However, the role of PTPN13 in clear cell renal cell carcinoma (ccRCC) is poorly understood. In the present study, we aimed to evaluate whether PTPN13 participates in the progression of ccRCC. Decreased expression of PTPN13 was found in ccRCC tissues, which predicted a shorter survival rate in ccRCC patients. PTPN13 expression was also lower in ccRCC cell lines, and the upregulation of PTPN13 repressed the proliferation, colony formation and invasion, but enhanced the apoptosis of ccRCC cells. In contrast, the silencing of PTPN13 produced the opposite effects. Further data showed that PTPN13 overexpression decreased the phosphorylation of Akt, while PTPN13 silencing increased the phosphorylation of Akt. Treatment with Akt inhibitor markedly abrogated the PTPN13 silencing-evoked oncogenic effect in ccRCC cells. Xenograft tumor experiments revealed that overexpression of PTPN13 remarkably restricted the tumor formation and growth of ccRCC cells in vivo associated with inactivation of Akt. In conclusion, our data demonstrated that overexpression of PTPN13 restricts the proliferation and invasion of ccRCC cells through inactivation of Akt. Our study suggests a tumor suppressive function of PTPN13 in ccRCC and highlights the potential role of PTPN13 in the progression of ccRCC.
Collapse
Affiliation(s)
- Qingzhi Long
- Department of Urology, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, 710061, China
| | - Jiping Sun
- Department of Nephrology, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, 710061, China
| | - Jia Lv
- Department of Nephrology, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, 710061, China
| | - Yu Liang
- Department of Nephrology, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, 710061, China
| | - Huixian Li
- Department of Nephrology, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, 710061, China
| | - Xudong Li
- Department of Urology, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, 710061, China.
| |
Collapse
|
6
|
Dicks M, Kock G, Kohl B, Zhong X, Pütz S, Heumann R, Erdmann KS, Stoll R. The binding affinity of PTPN13's tandem PDZ2/3 domain is allosterically modulated. BMC Mol Cell Biol 2019; 20:23. [PMID: 31286859 PMCID: PMC6615252 DOI: 10.1186/s12860-019-0203-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2019] [Accepted: 06/02/2019] [Indexed: 11/24/2022] Open
Abstract
Background Protein tyrosine phosphatase PTPN13, also known as PTP-BL in mice, is a large multi-domain non-transmembrane scaffolding protein with a molecular mass of 270 kDa. It is involved in the regulation of several cellular processes such as cytokinesis and actin-cytoskeletal rearrangement. The modular structure of PTPN13 consists of an N-terminal KIND domain, a FERM domain, and five PDZ domains, followed by a C-terminal protein tyrosine phosphatase domain. PDZ domains are among the most abundant protein modules and they play a crucial role in signal transduction of protein networks. Results Here, we have analysed the binding characteristics of the isolated PDZ domains 2 and 3 from PTPN13 and compared them to the tandem domain PDZ2/3, which interacts with 12 C-terminal residues of the tumour suppressor protein of APC, using heteronuclear multidimensional NMR spectroscopy. Furthermore, we could show for the first time that PRK2 is a weak binding partner of PDZ2 and we demonstrate that the presence of PDZ3 alters the binding affinity of PDZ2 for APC, suggesting an allosteric effect and thereby modulating the binding characteristics of PDZ2. A HADDOCK-based molecular model of the PDZ2/3 tandem domain from PTPN13 supports these results. Conclusions Our study of tandem PDZ2/3 in complex with APC suggests that the interaction of PDZ3 with PDZ2 induces an allosteric modulation within PDZ2 emanating from the back of the domain to the ligand binding site. Thus, the modified binding preference of PDZ2 for APC could be explained by an allosteric effect and provides further evidence for the pivotal function of PDZ2 in the PDZ123 domain triplet within PTPN13.
Collapse
Affiliation(s)
- Markus Dicks
- Biomolecular NMR, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, 44780, Bochum, Germany
| | - Gerd Kock
- Biomolecular NMR, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, 44780, Bochum, Germany
| | - Bastian Kohl
- Biomolecular NMR, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, 44780, Bochum, Germany
| | - Xueyin Zhong
- Biomolecular NMR, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, 44780, Bochum, Germany
| | - Stefanie Pütz
- Biomolecular NMR, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, 44780, Bochum, Germany
| | - Rolf Heumann
- Biochemistry II, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, 44780, Bochum, Germany
| | - Kai S Erdmann
- Department of Biomedical Science, University of Sheffield, S10 2TN, Sheffield, UK
| | - Raphael Stoll
- Biomolecular NMR, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, 44780, Bochum, Germany.
| |
Collapse
|
7
|
Kock G, Dicks M, Yip KT, Kohl B, Pütz S, Heumann R, Erdmann KS, Stoll R. Molecular Basis of Class III Ligand Recognition by PDZ3 in Murine Protein Tyrosine Phosphatase PTPN13. J Mol Biol 2018; 430:4275-4292. [PMID: 30189200 DOI: 10.1016/j.jmb.2018.08.023] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2018] [Revised: 07/31/2018] [Accepted: 08/23/2018] [Indexed: 12/26/2022]
Abstract
Protein tyrosine phosphatase PTPN13, also known as PTP-BL in mice, represents a large multi-domain non-transmembrane scaffolding protein that contains five consecutive PDZ domains. Here, we report the solution structures of the extended murine PTPN13 PDZ3 domain in its apo form and in complex with its physiological ligand, the carboxy-terminus of protein kinase C-related kinase-2 (PRK2), determined by multidimensional NMR spectroscopy. Both in its ligand-free state and when complexed to PRK2, PDZ3 of PTPN13 adopts the classical compact, globular D/E fold. PDZ3 of PTPN13 binds five carboxy-terminal amino acids of PRK2 via a groove located between the EB-strand and the DB-helix. The PRK2 peptide resides in the canonical PDZ3 binding cleft in an elongated manner and the amino acid side chains in position P0 and P-2, cysteine and aspartate, of the ligand face the groove between EB-strand and DB-helix, whereas the PRK2 side chains of tryptophan and alanine located in position P-1 and P-3 point away from the binding cleft. These structures are rare examples of selective class III ligand recognition by a PDZ domain and now provide a basis for the detailed structural investigation of the promiscuous interaction between the PDZ domains of PTPN13 and their ligands. They will also lead to a better understanding of the proposed scaffolding function of these domains in multi-protein complexes assembled by PTPN13 and could ultimately contribute to low molecular weight antagonists that might even act on the PRK2 signaling pathway to modulate rearrangements of the actin cytoskeleton.
Collapse
Affiliation(s)
- Gerd Kock
- Biomolecular NMR Spectroscopy, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, D-44780, Germany
| | - Markus Dicks
- Biomolecular NMR Spectroscopy, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, D-44780, Germany
| | - King Tuo Yip
- Biomolecular NMR Spectroscopy, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, D-44780, Germany
| | - Bastian Kohl
- Biomolecular NMR Spectroscopy, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, D-44780, Germany
| | - Stefanie Pütz
- Biomolecular NMR Spectroscopy, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, D-44780, Germany
| | - Rolf Heumann
- Molecular Neurobiochemistry, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, D-44780, Germany
| | - Kai S Erdmann
- Department of Biomedical Science, University of Sheffield, Sheffield, S10 2TN, United Kingdom
| | - Raphael Stoll
- Biomolecular NMR Spectroscopy, Faculty of Chemistry and Biochemistry, Ruhr-University of Bochum, D-44780, Germany.
| |
Collapse
|
8
|
Bamberg A, Redente EF, Groshong SD, Tuder RM, Cool CD, Keith RC, Edelman BL, Black BP, Cosgrove GP, Wynes MW, Curran-Everett D, De Langhe S, Ortiz LA, Thorburn A, Riches DWH. Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2018; 198:914-927. [PMID: 29727583 PMCID: PMC6173065 DOI: 10.1164/rccm.201707-1497oc] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Accepted: 05/04/2018] [Indexed: 01/11/2023] Open
Abstract
RATIONALE Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrotic interstitial lung disease characterized by (myo)fibroblast accumulation and collagen deposition. Resistance to Fas-induced apoptosis is thought to facilitate (myo)fibroblast persistence in fibrotic lung tissues by poorly understood mechanisms. OBJECTIVES To test the hypothesis that PTPN13 (protein tyrosine phosphatase-N13) is expressed by IPF lung (myo)fibroblasts, promotes their resistance to Fas-induced apoptosis, and contributes to the development of pulmonary fibrosis. METHODS PTPN13 was localized in lung tissues from patients with IPF and control subjects by immunohistochemical staining. Inhibition of PTPN13 function in primary IPF and normal lung (myo)fibroblasts was accomplished by: 1) downregulation with TNF-α (tumor necrosis factor-α)/IFN-γ, 2) siRNA knockdown, or 3) a cell-permeable Fas/PTPN13 interaction inhibitory peptide. The role of PTPN13 in the development of pulmonary fibrosis was assessed in mice with genetic deficiency of PTP-BL, the murine ortholog of PTPN13. MEASUREMENTS AND MAIN RESULTS PTPN13 was constitutively expressed by (myo)fibroblasts in the fibroblastic foci of patients with IPF. Human lung (myo)fibroblasts, which are resistant to Fas-induced apoptosis, basally expressed PTPN13 in vitro. TNF-α/IFN-γ or siRNA-mediated PTPN13 downregulation and peptide-mediated inhibition of the Fas/PTPN13 interaction in human lung (myo)fibroblasts promoted Fas-induced apoptosis. Bleomycin-challenged PTP-BL-/- mice, while developing inflammatory lung injury, exhibited reduced pulmonary fibrosis compared with wild-type mice. CONCLUSIONS These findings suggest that PTPN13 mediates the resistance of human lung (myo)fibroblasts to Fas-induced apoptosis and promotes pulmonary fibrosis in mice. Our results suggest that strategies aimed at interfering with PTPN13 expression or function may represent a novel strategy to reduce fibrosis in IPF.
Collapse
Affiliation(s)
- Alison Bamberg
- Program in Cell Biology, Department of Pediatrics
- Department of Immunology and Microbiology
| | - Elizabeth F. Redente
- Program in Cell Biology, Department of Pediatrics
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and
- Department of Research, Veterans Affairs Eastern Colorado Health Care System, Denver, Colorado
| | - Steve D. Groshong
- Department of Medicine, and
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and
| | - Rubin M. Tuder
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and
| | - Carlyne D. Cool
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and
| | - Rebecca C. Keith
- Department of Medicine, and
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and
| | | | | | - Gregory P. Cosgrove
- Department of Medicine, and
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and
| | - Murry W. Wynes
- Program in Cell Biology, Department of Pediatrics
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and
| | | | - Stijn De Langhe
- Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama; and
| | - Luis A. Ortiz
- Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Andrew Thorburn
- Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado
| | - David W. H. Riches
- Program in Cell Biology, Department of Pediatrics
- Department of Immunology and Microbiology
- Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, and
- Department of Pharmacology, University of Colorado School of Medicine, Aurora, Colorado
- Department of Research, Veterans Affairs Eastern Colorado Health Care System, Denver, Colorado
| |
Collapse
|
9
|
D'Hondt V, Lacroix-Triki M, Jarlier M, Boissiere-Michot F, Puech C, Coopman P, Katsaros D, Freiss G. High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome. Oncotarget 2017; 8:95662-95673. [PMID: 29221157 PMCID: PMC5707051 DOI: 10.18632/oncotarget.21175] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2017] [Accepted: 08/16/2017] [Indexed: 11/25/2022] Open
Abstract
Background Chromosome 4q loss of heterozygosity (LOH) is frequently observed in high-grade serous ovarian carcinoma (HGSOC). However, this LOH has not been clearly associated with the inactivation of any tumor suppressor gene(s). As the tumor suppressor gene PTPN13 is located on chromosome 4q21, we investigated its expression in HGSOC. Methods PTPN13 protein expression was investigated by immunohistochemistry (IHC) in normal ovary epithelium and in 30 HGSOC samples, whereas PTPN13 mRNA expression was quantified by RT-PCR in another independent cohort of 28 HGSOC samples. Patients in both cohorts were followed for more than 8.5 years. Results PTPN13 protein expression was lower in one third of HGSOC samples compared with normal ovary epithelium. In both cohorts, high PTPN13 expression level (mRNA or protein) in the tumor was associated with favorable outcome and significantly longer survival (HR=0.27; p=0.0087 and HR=0.42; p=0.03, respectively). Conclusion This study demonstrates, for the first time, that high PTPN13 expression level is a prognostic indicator of favorable outcome in patients with HGSOC. This finding, in conjunction with our previous mechanistic studies, suggests that PTPN13 loss, possibly by 4q LOH, enhances HGSOC aggressiveness and highlight the interest of studying PTPN13 signaling in HGSOC to identify new potential therapeutic targets.
Collapse
Affiliation(s)
- Véronique D'Hondt
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier F-34298, France.,Institut régional du Cancer de Montpellier, Montpellier F-34298, France
| | - Magalie Lacroix-Triki
- Département de Biologie et Pathologie Médicales, Gustave-Roussy Cancer Campus, 94805 Villejuif cedex, France
| | - Marta Jarlier
- Unité de Biométrie, Institut régional du Cancer de Montpellier, Montpellier F-34298, France
| | - Florence Boissiere-Michot
- Unité de Recherche Translationnelle, Institut Régional du Cancer de Montpellier, Montpellier F-34298, France
| | - Carole Puech
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier F-34298, France.,Institut régional du Cancer de Montpellier, Montpellier F-34298, France.,INSERM, U 1194, Montpellier F-34298, France.,Université de Montpellier, Montpellier F-34090, France
| | - Peter Coopman
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier F-34298, France.,Institut régional du Cancer de Montpellier, Montpellier F-34298, France.,INSERM, U 1194, Montpellier F-34298, France.,Université de Montpellier, Montpellier F-34090, France
| | - Dionyssios Katsaros
- Azienda Ospedaliero-Universitaria Cittadella Salute, Presidio S. Anna and Department of Surgical Science, Gynecology, University of Torino, Torino, Italy
| | - Gilles Freiss
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier F-34298, France.,Institut régional du Cancer de Montpellier, Montpellier F-34298, France.,INSERM, U 1194, Montpellier F-34298, France.,Université de Montpellier, Montpellier F-34090, France
| |
Collapse
|
10
|
Zhuang L, Shou T, Li K, Gao CL, Duan LC, Fang LZ, Zhang QY, Chen ZN, Zhang C, Yang ST, Li GF. MicroRNA-30e-5p promotes cell growth by targeting PTPN13 and indicates poor survival and recurrence in lung adenocarcinoma. J Cell Mol Med 2017; 21:2852-2862. [PMID: 28653805 PMCID: PMC5661247 DOI: 10.1111/jcmm.13198] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Accepted: 03/15/2017] [Indexed: 12/02/2022] Open
Abstract
Aberrant microRNA expression is involved in the regulation of various cellular processes, such as proliferation and metastasis in multiple diseases including cancers. MicroRNA‐30e‐5p (miR‐30e) was previously reported as an oncogenic or tumour suppressing miRNA in some malignancies, but its function in lung adenocarcinoma (LAC) remains largely undefined. In this study, we found that the expression of miR‐30e was increased in LAC tissues and cell lines, associated with tumour size and represented an independent prognostic factor for overall survival and recurrence of LAC patients. Further functional experiments showed that knockdown of miR‐30e suppressed cell growth while its overexpression promoted growth of LAC cells and xenografts in vitro and in vivo. Mechanistically, PTPN13 was identified as the direct target of miR‐30e in LAC, in which PTPN13 expression was down‐regulated in LAC tissues and showed the inverse correlation with miR‐30e expression. Overexpression of PTPN13 inhibited cell growth and rescued the proliferation‐promoting effect of miR‐30e through inhibition of the EGFR signalling. Altogether, our findings suggest that miR‐30e could function as an oncogene in LAC via targeting PTPN13 and act as a potential therapeutic target for treating LAC.
Collapse
Affiliation(s)
- Li Zhuang
- Department of Palliative Medicine, Palliative Medicine Research Center, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
| | - Tao Shou
- Department of Oncology, The First People's Hospital of Yunnan Province, Kunming, Yunnan Province, China
| | - Ke Li
- The Second Department of Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
| | - Chun-Lin Gao
- The Second Department of Medicine, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
| | - Lin-Can Duan
- Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
| | - Li-Zhou Fang
- The Second Department of Respiratory, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
| | - Qin-Yong Zhang
- Department of Pharmacy, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
| | - Zong-Ning Chen
- Department of Cardiology, The People's Hospital of Lijiang City, Lijiang, Yunnan Province, China
| | - Chao Zhang
- Cancer Treatment Center, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
| | - Shou-Tao Yang
- Department of Nursing, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
| | - Gao-Feng Li
- Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China
| |
Collapse
|
11
|
Sardina JL, López-Ruano G, Prieto-Bermejo R, Sánchez-Sánchez B, Pérez-Fernández A, Sánchez-Abarca LI, Pérez-Simón JA, Quintales L, Sánchez-Yagüe J, Llanillo M, Antequera F, Hernández-Hernández A. PTPN13 regulates cellular signalling and β-catenin function during megakaryocytic differentiation. Biochim Biophys Acta 2014; 1843:2886-99. [PMID: 25193362 DOI: 10.1016/j.bbamcr.2014.08.014] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Revised: 08/08/2014] [Accepted: 08/26/2014] [Indexed: 11/18/2022]
Abstract
PTPN13 is a high-molecular weight intracellular phosphatase with several isoforms that exhibits a highly modular structure. Although in recent years different roles have been described for PTPN13, we are still far from understanding its function in cell biology. Here we show that PTPN13 expression is activated during megakaryocytic differentiation at the protein and mRNA level. Our results show that the upregulation of PTPN13 inhibits megakaryocytic differentiation, while PTPN13 silencing triggers differentiation. The ability of PTPN13 to alter megakaryocytic differentiation can be explained by its capacity to regulate ERK and STAT signalling. Interestingly, the silencing of β-catenin produced the same effect as PTPN13 downregulation. We demonstrate that both proteins coimmunoprecipitate and colocalise. Moreover, we provide evidence showing that PTPN13 can regulate β-catenin phosphorylation, stability and transcriptional activity. Therefore, the ability of PTPN13 to control megakaryocytic differentiation must be intimately linked to the regulation of β-catenin function. Moreover, our results show for the first time that PTPN13 is stabilised upon Wnt signalling, which makes PTPN13 an important player in canonical Wnt signalling. Our results show that PTPN13 behaves as an important regulator of megakaryocytic differentiation in cell lines and also in murine haematopoietic progenitors. This importance can be explained by the ability of PTPN13 to regulate cellular signalling, and especially through the regulation of β-catenin stability and function. Our results hold true for different megakaryocytic cell lines and also for haematopoietic progenitors, suggesting that these two proteins may play a relevant role during in vivo megakaryopoiesis.
Collapse
Affiliation(s)
- José L Sardina
- Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain; IBFG, Instituto de Biología Funcional y Genómica, CSIC, Salamanca 37007, Spain
| | - Guillermo López-Ruano
- Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca 37007, Spain
| | - Rodrigo Prieto-Bermejo
- Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca 37007, Spain
| | - Beatriz Sánchez-Sánchez
- Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca 37007, Spain
| | - Alejandro Pérez-Fernández
- Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca 37007, Spain
| | | | - José Antonio Pérez-Simón
- Department of Hematology, Hospital Universitario Virgen del Rocío/IBIS/CSIC/University of Seville, Spain
| | - Luis Quintales
- IBFG, Instituto de Biología Funcional y Genómica, CSIC, Salamanca 37007, Spain
| | - Jesús Sánchez-Yagüe
- Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain
| | - Marcial Llanillo
- Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca 37007, Spain
| | - Francisco Antequera
- IBFG, Instituto de Biología Funcional y Genómica, CSIC, Salamanca 37007, Spain
| | - Angel Hernández-Hernández
- Department of Biochemistry and Molecular Biology, University of Salamanca, Salamanca, Spain; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca 37007, Spain.
| |
Collapse
|
12
|
Han X, Xue L, Zhou L, Gong L, Zhu S, Yao L, Wang S, Lan M, Li Y, Zhang W. The role of PTPN13 in invasion and metastasis of lung squamous cell carcinoma. Exp Mol Pathol 2013; 95:270-5. [PMID: 23906871 DOI: 10.1016/j.yexmp.2013.07.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2013] [Revised: 07/18/2013] [Accepted: 07/20/2013] [Indexed: 11/22/2022]
Abstract
OBJECTIVES PTPN13 is a new candidate tumor-suppressing gene. To investigate the PTPN13 expression and its potential function in the invasion and metastasis of lung squamous cell carcinoma (LSCC), we performed this study in 91 primary LSCC tissues and the adjacent non-cancerous tissues. METHODS The mRNA expression of PTPN13 and FAK was quantitated by reverse transcription polymerase chain reaction. The protein expression of PTPN13, focal adhesion kinase (FAK) and phosphorylated FAK (P-FAK) was evaluated using immunohistochemical staining and western blotting. The association among PTPN13 expression, FAK expression and the clinicopathological parameters were analyzed. RESULTS PTPN13 expression was down-regulated in LSCC, and was negatively correlated with the cancer grade and stage. FAK mRNA, as well as FAK protein level was elevated in LSCC tissues. P-FAK level, also found increased, had no association with FAK mRNA and FAK protein expression, but had a negative correlation with the PTPN13 expression. P-FAK level had a significant positive correlation with the TNM classification. CONCLUSION The over-expression of FAK and increased FAK phosphorylation plays an important role in the invasion and metastasis of LSCC.
Collapse
|